SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Renovo Plc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: nigel bates who wrote (31)8/29/2007 7:19:13 AM
From: nigel bates  Read Replies (1) of 40
 
28 August 2007 RENOVO GROUP PLC

APPOINTMENT OF DR JOHN HUTCHISON AS CHIEF MEDICAL OFFICER AND EXECUTIVE BOARD DIRECTOR

Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for
the prevention and reduction of scarring at multiple body sites, today announces
that, with immediate effect, Dr John Hutchison has been appointed to the Renovo
Executive team and Board as Chief Medical Officer and Dr Argeris (Jerry)
Karabelas has stepped down as a Non-executive Director of the Company.

Dr John Hutchison, aged 51, joins Renovo from Vernalis plc where he held a
number of Executive Director roles including Development Director and Chief
Medical Officer. Dr Hutchison began his industrial career as a clinical
pharmacologist with Fisons, before moving to experimental medicine with Astra
Pharmaceuticals Ltd.

In addition to being a UK registered physician, Dr Hutchison has a first class
Honours degree in Human Physiology and a PhD in Neuroscience from the University
of Liverpool. Dr Hutchison is a Fellow of the Royal College of Physicians and a
Fellow of the Faculty of Pharmaceutical Medicine in London.

Dr Argeris Karabelas was not considered to be independent of management, by
virtue of Care Capital previously owning a significant equity interest in the
Company. Renovo's balance of non independent to independent Directors therefore
remains the same and continues to comply with the principles and code of best
practice as set out in the Combined Code on Corporate Governance (issued July
2003).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News